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We investigated the suit-
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ducials for pancreatic cancer
patient radiation therapy
setup verification by
comparing stent, bony anat-
omy, and intratumoral fidu-
cials image registrations of
daily cone beam computed
tomography in 11 patients. In
67% of fractions, the stent
indicated tumor position
better than bony anatomy.
However, the difference be-
tween stent and fiducials was
>5 mm in 112 of 243 frac-
tions (46%). Therefore,
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http://dx.doi.org/10.1016/j.ijrobp.2014.03.029Purpose: Because of low soft-tissue contrast of cone beam computed tomography
(CBCT), fiducial markers are often used for radiation therapy patient setup verifica-
tion. For pancreatic cancer patients, biliary stents have been suggested as surrogate fi-
ducials. Using intratumoral fiducials as standard for tumor position, this study aims to
quantify the suitability of biliary stents for measuring interfractional and respiratory-
induced position variations of pancreatic tumors.
Methods and Materials: Eleven pancreatic cancer patients with intratumoral fiducials
and a biliary stent were included in this study. Daily CBCT scans (243 in total) were
registered with a reference CT scan, based on bony anatomy, on fiducial markers, and
on the biliary stent, respectively. We analyzed the differences in tumor position (ie,
markers center-of-mass position) among these 3 registrations. In addition, we
measured for 9 patients the magnitude of respiratory-induced motion (MM) of the
markers and of the stent on 4-dimensional CT (4DCT) and determined the difference
between these 2 magnitudes (DMM).
Results: The stent indicated tumor position better than bony anatomy in 67% of frac-
tions; the absolute difference between the markers and stent registration was >5 mm
in 46% of fractions and >10 mm in 20% of fractions. Large PTV margins (superior-
inferior direction, >19 mm) would be needed to account for this interfractional posi-
tion variability. On 4DCT, we found in superior-inferior direction a mean DMM of
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including patients with a
stent.Conclusions: For respiratory-induced motion, the mean DMM is small, but for indi-
vidual patients the absolute difference can be >4 mm. For interfractional position var-
iations, a stent is, on average, a better surrogate fiducial than bony anatomy, but large
PTV margins would still be required. Therefore, intratumoral fiducials are recom-
mended for online setup verification for all pancreatic patients scheduled for radiation
therapy, including patients with a biliary stent.  2014 Elsevier Inc.Introduction
The ability to take full advantage of the potential benefit of
radiochemotherapy for resectable and borderline resectable
pancreatic cancer (1) is curtailed by the inevitable radiation
dose to surrounding organs at risk (OARs), such as stomach
and small intestine. For the pancreas, poorly visible on cone
beam computed tomography (CBCT) because of the low
soft-tissue contrast of this technique, intratumoral fiducial
markers can be used for patient setup verification. This
allows the diminishing of daily setup errors and a decrease
of the required planning target volume (PTV) margins, thus
helping to limit the dose to OARs (2). In addition, fiducial
markers can be used in quantifying respiratory-induced
motion, for example on 4-dimensional CT (4DCT), to
determine treatment margins (3). However, although
endoscopic implantation of such fiducials can be performed
safely (4, 5), it does entail an additional medical procedure,
and patients could present with contraindications for
endoscopy. Therefore, alternatives to the use of especially
implanted fiducials are welcome.
Several anatomical markers have been investigated for
their suitability to quantify respiratory-induced motion of
pancreatic tumors, with limited success. Feng et al found
that the positions of both diaphragm and abdominal wall
did not correlate well with tumor position (6). Likewise, the
sternum was found to show poor correlation with gross
tumor volume (GTV) position (7).
Because of their proximity to the pancreatic head,
biliary stentsdoften needed in pancreatic head cancer pa-
tients to relieve obstructive jaundicedhave also been
investigated as surrogate fiducial markers. For respiratory-
induced motion, low correlations were found between stent
and delineated GTV (7, 8). For pancreatic tumors, however,
large delineation errors have been reported (9), challenging
the appropriateness of a delineated GTV as benchmark for
pancreatic tumor position. For interfractional position
variation, so far no comparison has been made between a
stent and other fiducial markers.
Nevertheless, despite the uncertainty regarding their ac-
curacy, biliary stents have been used regularly as surrogate
markers for pancreatic tumor position and motion (3, 10-13).
This necessitates a more comprehensive examination of the
correlation between the positions of biliary stents and
pancreatic tumors, with reliable tumor localization. On CT,
4DCT and CBCT, such reliable localization can be provided
by intratumoral fiducial markers. These markers have beendemonstrated to be stable within the tumor and can therefore
be regarded as a standard for tumor position (2).
The aim of our current study was to quantify the suitability
of biliary stents as surrogate markers for interfractional tumor
position variation and respiratory-induced motion in pancre-
atic cancer patients. We registered daily CBCT scans with a
reference CT, based on bony anatomy, on a stent, and on
intratumoral fiducial markers, respectively, and determined
the difference in tumor position among these 3 registrations. In
addition, we quantified the difference in position variation
between stent and markers during respiration, using 4DCT.Methods and Materials
Patient population
In a group of 18 consecutive pancreatic patients who had
received intratumoral fiducials visible on the treatment
planning CT, 11 also had a biliary stent placed. These 11
patients, treated between October 2010 and May 2013,
were included in this retrospective study. All tumors were
located in the pancreatic head. Five patients had received a
3.3-mm-diameter polyethylene endoprosthetic (Cook
Medical, Winston-Salem, NC) (Fig. 1a); 6 patients had
received a 10-mm-diameter metal WallFlex stent (Boston
Scientific, Natick, MA) of varying length and type. Patient
details are listed in Table 1, with patient numbering
consistent with that in Van der Horst et al (2).
Two types of gold fiducials had been implanted: Visicoil
(RadioMed, Barlett, TN) and Gold Anchor (Naslund
Medical AB, Huddinge, Sweden) (2, 4). The fiducials (2-4
per patient) were implanted under endoscopic ultrasound
guidance in a previously described procedure (4), within
the framework of a clinical feasibility study approved by
our institution’s medical ethics committee; patients had
given written informed consent. Planned radiation therapy
was 28  1.8 Gy (patients 16 and 18) or 25  2.0 Gy, all
with concurrent gemcitabine-based chemotherapy.
Reference CT and CBCT imaging
For treatment planning, a conventional CT, 4DCT (10 res-
piratory bins) and/or positron emission tomography CT scan
were made before treatment. For all CTs (slice thickness,
2.5 mm; pixel size, 1  1 mm2), the scan area ranged from
2 cm above the diaphragm to the iliac crest. During imaging
Fig. 1. Elekta x-ray volume imaging (XVI) overlays of reference computed tomography (refCT; purple) and cone beam
computed tomography (CBCT; green) for patient 2: with the polyethylene stent registered (a), the markers (b, white arrow) are
displaced. Inner and outer red contour indicate gross tumor volume and planning target volume, respectively. CBCT projection
images for patient 18 on (c) day 13 (first fraction) and (d) day 40, showing stent migration and shape change. A color version of
this Figure is available at www.redjournal.org.
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in supine position, arms raised above their head.
When possible, we used the 4DCT average intensity
projection as reference CT (refCT) for CBCT registration;
otherwise we used the treatment planning CT. Nine patients
had received a 4DCT; patients 2 and 8 had not. For patient
1, we did not use the 4DCT for CBCT registration, because
the scan had been performed in the third week of treatment.
Daily CBCTs were obtained before irradiation (Synergy,
Elekta Oncology Systems, Crawley, UK) and used for po-
sition verification. A total of 27 scheduled fractions were not
delivered and 11 CBCTs were not retrievable, resulting in
243 CBCTs in total (9-27 per patient) included in our study.
Image registration
Each CBCT was rigidly registered to the refCT using 3D
translations and rotations. Registrations were performed(all by trained observer R.d.J.) within Elekta x-ray volume
imaging (XVI) software (version 4.5; Elekta Oncology
Systems), based on bony anatomy, stent, and fiducial
markers as a group, respectively (Fig. 1a and b). For the
bony anatomy registration, a clipbox, placed around part of
the thoracic/lumbar vertebrae (the most stable bony anat-
omy closest to the pancreas), and the bone algorithm
(chamfer matching) were used. The markers registrations
and stent registrations were done using a mask (shaped
region of interest) combined with the seed (chamfer
matching) or gray value algorithm. All registrations were
visually checked and manually adjusted when necessary.
When the stent registration was difficult because of shape
change of the stent, a manual registration was performed,
which aimed to achieve the best visual 3D overlap.
We obtained the coordinates of each marker in the
refCT. For each marker individually, we manually regis-
tered each CBCT with the refCT (translations only). From
Table 1 Patient characteristics, with patient numbering consistent with that in Van der Horst et al (2)
Patient Age, sex No. of CBCTs
No. of markers
in refCT Type of markers Type of stent
1 66, M 24 3 Visicoil Cook, 10 Fr 9 cm
2 42, M 18 3 Visicoil Cook, 10 Fr 9 cm
3 59, M 25 2 Visicoil Cook, 10 Fr 9 cm
4 46, F 24 3 Visicoil WallFlex 40 mm uncovered
6 68, F 24 2 Visicoil WallFlex 60 mm fully covered
7 77, F 25 2 Visicoil WallFlex 60 mm uncovered
8 49, M 25 2 Visicoil WallFlex 60 mm fully covered
13 75, M 18 4 Visicoil Cook, 10 Fr 9 cm
16 54, F 9 2 Gold Anchor WallFlex 40 mm uncovered
17 56, M 24 2 Gold Anchor Cook, 10 Fr 9 cm
18 77, M 27 2 Visicoil þ Gold Anchor WallFlex 60 mm fully covered
Abbreviations: CBCT Z cone beam computed tomography; F Z female; M Z male; refCT Z reference computed tomography.
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(MP), that is, the 3D position of the center of mass of the
markers, based on the method described in Van der Horst et
al (2). We used MP as a measure for tumor position in our
comparisons between different image registration strate-
gies. For this, we defined MPbone, MPstent, and MPmark as
the MP after bony anatomy, stent, and markers registration,
respectively. We defined DMPstentemark as the difference in
MP between stent and markers registration, that is,
MPstenteMPmark; analogous for DMPstentebone and
DMPmarkebone.
CBCT data analysis
For each patient, we plotted and analyzed the distributions
of DMPstentemark for the left-right (L-R), superior-inferior
(S-I) and anterior-posterior (A-P) directions, with the
positive directions in L, S, and A, as well as for the vector
distances; group means and standard deviations (SDs)
were calculated. We determined the numbers of fractions
for which the vector distance of DMPstentemark was
>5 mm and >10 mm, respectively. To establish whether
there were changes over time, we applied linear fits to
DMPstentemark as a function of day since refCT and
determined significance of slope for each fit, in each
direction.
To obtain insight into the positional relation between
stent and markers, we plotted for each patient
DMPstentebone against DMPmarkebone, for each direction
separately. We applied linear fits to these correlation plots
and determined Pearson correlation coefficient R. When
stent and markers move with respect to bony anatomy in a
rigid configuration relative to each other, R will approach 1.
In addition, the linear fits (y Z Ax þ B) will have slope
AZ 1 and, without a systematic difference, will lie on the
diagonal (y Z x). A systematic difference, however,
introduced by for example stent migration, will shift this
fitted line (Bs0), whereas an under- or overestimation of
motion by the stent will decrease (A<1) or increase (A>1)
the slope, respectively. Furthermore, we determined thenumber of fractions for which the stent indicated tumor
position better than bony anatomy, that is, the number for
which jMPstenteMPmarkj<jMPmarkeMPbonej.
Respiratory-induced motion: 4DCT analysis
We investigated the use of biliary stents as surrogate fidu-
cials for respiratory-induced pancreatic tumor motion on
4DCT. For each patient, we used manual rigid image
registration (XVI; translations only) of each respiratory
phase with phase 0 (end-inhalation), based on stent and on
fiducial markers, obtaining relative displacements for all
phases. When stent registration exhibited difficulties
because of shape change or rotation, the stent end located
closest to the PTV was registered. We determined the range
in displacement difference between stent and markers over
the respiratory cycle, and calculated the difference in ob-
tained motion magnitude MM (peak-to-peak motion),
DMM Z MMstenteMMmark, in each direction.Results
Interfractional position variation
We found a group mean DMPstentemark of 1.3 (SD 2.7) mm,
e0.4 (7.4) mm, and e0.8 (2.8) mm, in the L-R, S-I, and A-
P directions, respectively (nZ243). The DMPstentemark
vector distance ranged from 0.1 to 23.0 mm (mean,
6.6 mm; SD, 5.4 mm). Distributions per patient varied
greatly (Fig. 2). The widest distributions were found in S-I,
in which direction the means varied from e16.9 to 8.7 mm.
DMPstentemark (vector distance) was >5 mm for 112 frac-
tions (46%); for 20% of fractions (49 fractions in 7 pa-
tients) the difference was >10 mm.
Significant time trends for DMPstentemark as a function of
day since refCT were found for 5 patients (supplementary
Table E1), with the largest trends in S-I direction
(supplementary Fig. E1). To illustrate the differences be-
tween patients in behavior of stent and markers,
Fig. 2. Box plots for difference in markers position (MP)
between stent and markers registration (DMPstentemark) in
(a) left-right, (b) superior-inferior, and (c) anterior-posterior
directions, and for (d) vector distance.
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of treatment day for 3 typical patients (Fig. 3). Stent and
markers can either have a difference that increases over
time (patient 4), or behave alike (patient 7), yielding narrow
distributions around zero for DMPstentemark (Fig. 2a-c, pa-
tient 7), or show a systematic shift (patient 8).
Figure 4 shows the correlation plots for S-I, the direction
of largest position deviations; L-R and A-P are shown in
Figs. E2 and E3. In S-I, the stent underestimated tumor
displacement (A<1) for all patients; strong correlations
(R>0.8) were found for 5 patients (mean slope, 0.80; slope
range, 0.68-0.91). Systematic shifts ranged from e17.8 to
9.7 mm. For 164 of 243 fractions (67%), the stent was a
better surrogate for tumor position than bony anatomy(vector distance). In L-R, S-I, and A-P, this was the case for
181 (74%), 139 (57%), and 146 (60%) of 243 fractions,
respectively.
Respiratory-induced motion
The respiratory-induced motion was largest in the S-I di-
rection. In Figure 5, the S-I displacements of stent and
markers, and the difference between them, are plotted
against respiratory phase for 9 patients; L-R and A-P are
shown in Figs. E4 and E5. For phase 1 in patient 3 (Fig. 5b)
and phases 8 and 9 in patient 18 (Fig. 5i), the markers could
not be registered because of 4DCT motion artefacts. For
patients 6, 7, and 17, we experienced difficulties with stent
registration because of stent shape change and/or rotation
over the respiratory cycle (Figs. 5d, e, and h). For patient
17, this resulted in large differences between the stent and
markers in S-I and A-P, up to 4.9 mm and e8.6 mm,
respectively. For the remaining 8 patients, DMM ranged
from e2.9 to e0.2 mm (mean, e1.3 mm), e2.6 to 2.6 mm
(0.1 mm), and e2.2 to 2.1 mm (0.4 mm), in L-R, S-I, and
A-P, respectively.
Discussion
We compared CBCT image registrations based on intra-
tumoral fiducials and on a biliary stent and found large
differences (up to 23 mm) in tumor position. In 67% of
fractions, the stent was a better surrogate fiducial than bony
anatomy. For the magnitude of respiratory-induced motion
on 4DCT, the absolute mean difference between stent and
fiducials was limited (<1.5 mm), but for individual pa-
tients, substantial differences (up to 8.4 mm) were seen.
Possible uncertainties from delineation errors were
avoided by the use of intratumoral markers as a benchmark
for tumor position rather than delineated target volumes, as
used in other studies (7, 8). The observed discrepancies
between markers and stent signify the limitations of using a
biliary stent as fiducial for pancreatic tumor position.
Interfractional position variation
In the clinic, image registration of CBCT with a refCT is
used to determine the translations needed to correct the
patient’s treatment position. Within the analysis software
(XVI), these setup corrections are calculated by converting
obtained rotations into additional translations such that the
correction reference point (ie, the PTV’s center of mass)
remains fixed. For any fiducial in a rigid configuration with
the tumor, this approach will give the desired result. That is,
after patient setup correction the PTV might be rotated with
respect to the refCT (as our treatment tables allow only for
translations), but its center of mass will be located at the
intended position. For the intratumoral fiducials, we can
indeed assume such a rigid configuration, based on the lack
of change in interfiducial distance that we found for all
Fig. 3. For 3 patients, difference in markers position (MP) between markers and bony anatomy registrations (C) and
between stent and bony anatomy registrations (B) relative to the reference computed tomography (refCT) for each cone
beam computed tomography scan in the left-right, superior-inferior, and anterior-posterior directions, illustrating the dif-
ferences in behavior between stent and markers (see Results).
van der Horst et al. International Journal of Radiation Oncology  Biology  Physics646these patients, indicating an absence of fiducial migration
(2). Even though the common bile duct, in which a biliary
stent is placed, travels through the pancreatic head where it
connects to the pancreatic duct, our results show that, for
pancreatic head tumors, the tumor-stent configuration is not
rigid; while registering the stent, the markers are often
displaced with respect to their position on the refCT
(Fig. 1a and b). For such a nonrigid surrogate, the extent of
the introduced position deviation will depend on the
amount of translation and rotation between surrogate fidu-
cial and tumor. In addition, for rotations, the error will
increase with the distance between surrogate and correction
reference point.
To further investigate the influence of stent rotations, we
adopted a second strategy of stent registration: while
keeping the rotations fixed to the rotations from the bony
anatomy match, we registered on the inferior stent end,
which was closest to the PTV. This alternative strategy
improved results in some directions for some patients.
However, overall results worsened, with fits further from
the ideal y Z x relation and lower correlation coefficients
(alternative S-I correlation plots are shown in Fig. E6).
For interfractional position variations of the tumor, the
biliary stent often performed better as a surrogate fiducial
than bony anatomy. However, stents are subject to shape
change (as both biliary duct and stent are flexible), to
migration within the biliary duct, and to replacement (eg,after obstruction). Shape changes of the stent are likely to
be detected when they result in incompatible shapes be-
tween refCT and CBCT. Migration can be more difficult to
notice; with the stent being a single fiducial, migration
cannot be detected by monitoring interfiducial distances. If
migration remains undetected, a systematic setup error will
be introduced when using the stent for setup verification.
Stent migration was observed for patient 6, for whom
migration took place in the time between refCT and first
CBCT scan, as well as for patient 18, whose stent migrated
during the course of treatment (Fig. 1c and d and Fig. 4k).
The systematic errors that would have been introduced
were large; in the S-I direction, approximately e18 mm
(patient 6) and 11 mm (patient 18). Both patients had
received a covered metal stent, for which migration is re-
ported to occur more often than for uncovered metal stents
(14). We observed significant time trends for 5 patients.
Besides migration, changes in overall patient anatomy
(weight loss, bowel filling) could be the source of these
trends. An additional problem arises for straight stents, as
main-axis rotations can yield degeneracy in the registration
optimization. For patient 16, such degeneracy was seen,
albeit with limited effect on DMPstentemark (Fig. E7); all
other stents were curved, precluding this problem.
Overall, large setup errors remained, although they
were on average smaller when using stents as surrogate
fiducials rather than bony anatomy. The CTV-to-PTV
Fig. 4. For each patient, the correlation of markers position (MP) between stent and markers registrations, both relative to
bony anatomy, in the superior-inferior direction. Note: Scales of axes differ in (e) and (k).
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errors can be determined by using, for example, the
margin recipe 2.5Sþ0.7s, with S the group systematic
error and s the group random error (15). For our limited
group of 11 patients, bony anatomy registration yielded
margin contributions of 10.8 mm (L-R), 18.3 mm (S-I),
and 9.0 mm (A-P), comparable to what we reported earlier
(2) (supplementary Table E2 provides calculations). The
stent registrations yielded margin contributions of 6.8 mm,
19.1 mm, and 6.9 mm, respectively. Thus, when using a
stent instead of bony anatomy for patient setup verifica-
tion, PTV reductions might be very limited or even absent.
Note that this is only part of the margin accounting for
interfractional displacement, not incorporating other
components such as delineation errors. We would like to
stress that, for a more accurate estimate of S and s and
therefore of PTV margin contributions, a larger patient
cohort is needed.Respiratory-induced motion
In the literature, biliary stents are used to quantify
respiratory-induced motion of pancreatic tumors (3, 10-13).When using this to determine treatment margins, an error in
measured motion can result in a suboptimal target volume.
Although Goldstein et al found for all differences in
displacement >1 mm between the stent and GTV, an un-
derestimation of the respiratory-induced motion by the
stent (superior end), our data showed both over- and un-
derestimation by the stent (7). Differences were small for
some patients, but were >2 mm in 1 or more directions for
5 of 9 patients, comparable to the results reported by
Goldstein et al, who found a difference >2 mm in 10 of 20
patients (7). Therefore, using a stent to determine
respiratory-induced motion magnitude should be reconsid-
ered when another method is available; uncertainties must
be dealt with appropriately.
Conclusion
Biliary stents do not remain in a rigid configuration with
intratumoral fiducials for pancreatic head tumors. Using a stent
for image guided radiation therapy is beneficial compared to
using bony anatomy, but large margins are still needed to ac-
count for the interfractional uncertainties. The possibility of
unrecognized stent migration is an additional disadvantage.
Fig. 5. For 9 patients, displacements in superior-inferior direction of stent (;) and markers (D) and the difference (C), as
a function of 4-dimensional computed tomography respiratory phase, relative to phase 0 (end-inhalation). For each patient,
the range of difference and difference in magnitude of respiratory-induced motion (DMM) are indicated.
van der Horst et al. International Journal of Radiation Oncology  Biology  Physics648For respiratory-induced motion visible on 4DCT, the differ-
ences are smaller but nonetheless present. Therefore, intra-
tumoral markers for online patient setup verification should be
considered for all pancreatic cancer patients scheduled for ra-
diation therapy, even for those with a biliary stent.
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